Research Article

Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety

Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain

Search for more papers by this author

Carmen Belmonte

Search for more papers by this author

Nieves Derqui-Fernández

Search for more papers by this author

Teresa Cabaleiro

Search for more papers by this author

Manuel Román

UICEC Hospital Universitario de la Princesa, Plataforma SCReN (Spanish Clinical Reseach Network), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain

Search for more papers by this author

Dolores Ochoa

UICEC Hospital Universitario de la Princesa, Plataforma SCReN (Spanish Clinical Reseach Network), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain

Search for more papers by this author

María Talegón

Search for more papers by this author

María C Ovejero-Benito

Search for more papers by this author

Francisco Abad-Santos

*Author for correspondence: Tel.: +34 915202425; Fax: +34 915202540;

E-mail Address: francisco.abad@salud.madrid.org

UICEC Hospital Universitario de la Princesa, Plataforma SCReN (Spanish Clinical Reseach Network), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain

Search for more papers by this author

Published Online:24 Oct 2017https://doi.org/10.2217/pgs-2017-0116

View article

Abstract

Aim: The aim was to evaluate the effect of polymorphisms in metabolizing enzymes and transporters on the pharmacokinetics, pharmacodynamics and adverse effects of trazodone in healthy volunteers. Materials & methods: 36 healthy volunteers receiving a single 100-mg oral dose of trazodone were genotyped for 11 variants in CYP3A4, CYP3A5, CYP2D6 and ABCB1 by real-time PCR. Plasma concentrations were measured using liquid chromatography-tandem mass spectrometry method. Results & conclusion: Sex affected the pharmacokinetics of trazodone with higher clearance in women. Polymorphisms in ABCB1, but not in CYP3A or CYP2D6, influenced trazodone pharmacokinetics. Trazodone decreased blood pressure and prolonged the corrected QT interval interval. CYP2D6 and ABCB1 polymorphisms were associated with the incidence of dizziness and prolonged corrected QT interval, respectively. Subjects with adverse drug reactions had lower concentrations of trazodone suggesting its metabolite (m-chlorophenylpiperazine) could be responsible for these effects.

Keywords:

References

1 Marek GJ, McDougle CJ, Price LH, Seiden LS. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl.) 109(1–2), 2–11 (1992).
Medline CASGoogle Scholar
2 Brogden RN, Heel RC, Speight TM, Avery GS. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs 21(6), 401–429 (1981).
Medline CASGoogle Scholar
3 Hamik A, Peroutka SJ. 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol. Psychiatry 25(5), 569–575 (1989).
Medline CASGoogle Scholar
4 Kahn RS, Wetzler S. M-chlorophenylpiperazine as a probe of serotonin function. Biol. Psychiatry 30(11), 1139–1166 (1991).
Medline CASGoogle Scholar
5 Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J. Psychopharmacol. Oxf. Engl. (3), 235–241 (2005).
MedlineGoogle Scholar
6 Baumann MH, Ayestas MA, Dersch CM, Rothman RB. 1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 24(5), 492–501 (2001).
Medline CASGoogle Scholar
7 Pettibone DJ, Williams M. Serotonin-releasing effects of substituted piperazines in vitro. Biochem. Pharmacol. 33(9), 1531–1535 (1984).
Medline CASGoogle Scholar
8 Fiorella D, Rabin RA, Winter JC. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl.) 119(2), 222–230 (1995).
Medline CASGoogle Scholar
9 Khouzam HR. A review of trazodone use in psychiatric and medical conditions. Postgrad. Med. 129(1), 140–148 (2017).
MedlineGoogle Scholar
10 Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab. Dispos. Biol. Fate Chem. 26(6), 572–575 (1998).
Medline CASGoogle Scholar
11 Wen B, Ma L, Rodrigues AD, Zhu M. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab. Dispos. Biol. Fate Chem. 36(5), 841–850 (2008).
Medline CASGoogle Scholar
12 Westlind-Johnsson A, Hermann R, Huennemeyer A et al. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol. Ther. 79(4), 339–349 (2006).
Medline CASGoogle Scholar
13 Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RHN. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 14(1), 47–62 (2013).
CASGoogle Scholar
14 Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383–391 (2001).
Medline CASGoogle Scholar
15 CYP2D6 allele nomenclature (2017). www.cypalleles.ki.se/cyp2d6.htm.
Google Scholar
16 Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234–242 (2008).
Medline CASGoogle Scholar
17 Mihara K, Otani K, Suzuki A et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology (Berl.) 133(1), 95–98 (1997).
Medline CASGoogle Scholar
18 Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 6(5), 610–617 (1996).
Medline CASGoogle Scholar
19 Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361–398 (1999).
Medline CASGoogle Scholar
20 Yi S-Y, Hong K-S, Lim H-S et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. 76(5), 418–427 (2004).
Medline CASGoogle Scholar
21 Miura M, Satoh S, Tada H et al. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. Int. J. Clin. Pharmacol. Ther. 44(12), 605–613 (2006).
Medline CASGoogle Scholar
22 Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473–3478 (2000).
Medline CASGoogle Scholar
23 Störmer E, von Moltke LL, Perloff MD, Greenblatt DJ. P-glycoprotein interactions of nefazodone and trazodone in cell culture. J. Clin. Pharmacol. 41(7), 708–714 (2001).
Medline CASGoogle Scholar
24 Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother. Psychosom. 85(5), 270–288 (2016).
MedlineGoogle Scholar
25 Mittur A. Trazodone: properties and utility in multiple disorders. Expert Rev. Clin. Pharmacol. 4(2), 181–196 (2011).
Medline CASGoogle Scholar
26 US FDA label information for trazodone. https://dailymed.nlm.nih.gov/dailymed/index.cfm.
Google Scholar
27 Service JA, Waring WS. QT prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin. Toxicol. Phila. Pa. 46(1), 71–73 (2008).
Medline CASGoogle Scholar
28 Levenson JL. Prolonged QT interval after trazodone overdose. Am. J. Psychiatry 156(6), 969–970 (1999).
Medline CASGoogle Scholar
29 Jayaram G, Rao P. Safety of trazodone as a sleep agent for inpatients. Psychosomatics 46(4), 367–369 (2005).
MedlineGoogle Scholar
30 Bazett HC. An analysis of time relations of the electrocardiogram. Heart 7, 353–370 (1920).
Google Scholar
31 ICH Harmonized Tripartite Guideline E14 (2005). The clinical evaluation of QT/QTcinterval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. www.ich.org/cache/compo7276-254-1.html.
Google Scholar
32 Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin. Pharmacol. Ther. 21(3), 247–254 (1977).
Medline CASGoogle Scholar
33 Apellániz-Ruiz M, Inglada-Pérez L, Naranjo MEG et al. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics J. 15(3), 288–292 (2015).
Medline CASGoogle Scholar
34 Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3(6), 1101–1108 (2008).
Medline CASGoogle Scholar
35 Hardy–Weinberg equilibrium. https://ihg.gsf.de/cgi-bin/hw/hwa1.pl.
Google Scholar
36 European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence (2010). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
Google Scholar
37 Roden DM. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350(10), 1013–1022 (2004).
Medline CASGoogle Scholar
38 Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam. Clin. Pharmacol. 16(2), 147–156 (2002).
Medline CASGoogle Scholar
39 Ensembl data. ABCB1 rs1045642. http://e85.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=7:87508829–87509829;v=rs1045642;vdb=variation;vf=749288.
Google Scholar
40 Ensembl data. CYP3A4 rs67666821. www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=7:99757684–99758683;v=rs67666821;vdb=variation;vf=12903884.
Google Scholar
41 Ensembl data. CYP3A5 rs776746. www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=7:99672416–99673416;v=rs776746;vdb=variation;vf=550116.
Google Scholar
42 1000 Genomes Project Consortium, Auton A, Brooks LD et al. A global reference for human genetic variation. Nature 526(7571), 68–74 (2015).
MedlineGoogle Scholar
43 Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics (2), 229–243 (2002).
Google Scholar
44 Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. Off. J. Am. Coll. Med. Genet. 19(1), 69–76 (2016).
Google Scholar
45 Loeuillet C, Weale M, Deutsch S et al. Promoter polymorphisms and allelic imbalance in ABCB1 expression. Pharmacogenet. Genomics 17(11), 951–959 (2007).
Medline CASGoogle Scholar
46 Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM, Williams LM. ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am. J. Psychiatry 172(8), 751–759 (2015).
MedlineGoogle Scholar
47 Komar AA. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 8(8), 1075–1080 (2007).
CASGoogle Scholar
48 Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J. Clin. Pharmacol. 48(11), 1350–1355 (2008).
Medline CASGoogle Scholar
49 Schwartz JB. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42(2), 107–121 (2003).
Medline CASGoogle Scholar
50 Maranon R, Reckelhoff JF. Sex and gender differences in control of blood pressure. Clin. Sci. Lond. Engl. 1979 125(7), 311–318 (2013).
Google Scholar
51 Rabkin SW. Impact of age and sex on QT prolongation in patients receiving psychotropics. Can. J. Psychiatry. Rev. Can. Psychiatr. 60(5), 206–214 (2015).
MedlineGoogle Scholar
52 Jackson WK, Roose SP, Glassman AH. Cardiovascular toxicity of antidepressant medications. Psychopathology 20(Suppl. 1), 64–74 (1987).
MedlineGoogle Scholar
53 Wittebole X, Jacquet L, Wallemacq P, Hantson P. Trazodone poisoning with torsades de pointe and prolong ed need for inotropic support. Clin. Toxicol. 38, 248 (2000).
Google Scholar
54 Dockens RC, Greene DS, Barbhaiya RH. Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. J. Clin. Pharmacol. 36(2), 160–167 (1996).
Medline CASGoogle Scholar
55 Hodgson K, Tansey KE, Uher R et al. Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology (Berl.) 232(14), 2609–2617 (2015).
Medline CASGoogle Scholar
56 Maes M, Westenberg H, Vandoolaeghe E et al. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J. Clin. Psychopharmacol. 17(5), 358–364 (1997).
Medline CASGoogle Scholar

Vol. 18, No. 16

Metrics

Downloaded 480 times

History

Received 26 June 2017

Accepted 3 August 2017

Published online 24 October 2017

Published in print November 2017

Information

Keywords

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval and have followed the principles outlined in the Declaration of Helsinki for all human investigations. In addition, informed consent has been obtained from the participants involved.

Acknowledgements

The authors are grateful to the volunteers and the effort of the staff of the Clinical Trial Unit of Hospital Universitario de la Princesa.

Financial & competing interests disclosure

F Abad-Santos and D Ochoa have been consultants or investigators in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Chemo, Cinfa, FAES, Farmalíder, Ferrer, GlaxoSmithKline, Galenicum, Gilead, Janssen-Cilag, Kern, Normon, Novartis, Servier, Silverpharma, Teva and Zambon. M Saiz-Rodriguez is co-financed by Consejería de Educación, Juventud y Deporte from Comunidad de Madrid and Fondo Social Europeo. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download